SOURCE: Regen BioPharma Inc.

September 16, 2014 11:43 ET

Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer

Invention Leverages Research Discoveries in Development of dCellVax for New Cancer Immunotherapy Product

SAN DIEGO, CA--(Marketwired - Sep 16, 2014) - Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer. 

The patent application describes the utilization of gene silencing, which is the basis of the Company's dCellVax product, together with specific peptides that have previously been demonstrated to stimulate aspects of the innate immune system that is effective at inducing tumor regression.

"To my knowledge there is only one reproducible system in which cancer is destroyed by the immune system, this is the SR/CR mice developed by Wake Forest University1. In these mice, which are resistant to challenges with various tumors, the 'innate' and not the 'adaptive' immune system is responsible for eradication of the cancer," said Thomas Ichim, Ph.D., Chief Scientific Officer of Regen BioPharma. "By following the example of nature and focusing augmenting immune responses that are already known to be effective, we believe we are pioneering a novel approach to treatment of cancer."

The immune system is divided into "innate," which recognizes threats to the body regardless of prior exposures to the threat, and "adaptive," which recognizes threats that the body has previously been exposed to. The majority of cancer immunotherapies in clinical development and FDA trials, including checkpoint inhibitors and CAR-T cells work through the "adaptive" immune system. 

"While our efforts are focused on moving forward towards initiation of our HemaXellerate clinical trial and filing the IND for dCellVax, intellectual property on these novel products positions us for the possibility of licensing and co-development deals, which does not detract from the core developmental operations," said David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc.

The Company is currently preparing to file an IND application on its dCellVax therapy, which involves gene silencing for treating cancer.

About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.

Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

References

1 Hicks AM et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings of the National Academy of Sciences USA, 2006, 103:7753.

Contact Information

  • Contact:
    Regen BioPharma Inc.
    David R. Koos, PhD
    Chairman & Chief Executive Officer
    Phone: 619-702-1404
    Fax: 619.330.2328
    www.regenbiopharma.com